First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

NCT03015207 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Metabolism and Nutrition Disorder
Obesity

Interventions

DRUG: NNC0194-0499
DRUG: Placebo

Sponsor

Novo Nordisk A/S